- Conditions
- Crigler-Najjar Syndrome
- Interventions
- AT342
- Genetic
- Lead sponsor
- Audentes Therapeutics
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- The Bronx, New York • Strasburg, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1609–1632
of 7,392
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Valproic Acid and Levocarnitine, Placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Columbus, Ohio + 2 more
- Conditions
- Cancer
- Interventions
- IMC-RON8
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Detroit, Michigan • New York, New York
- Conditions
- Radiation-Induced Xerostomia and Hyposalivation
- Interventions
- RXRG001, Placebo
- Biological
- Lead sponsor
- RiboX Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage IV, Fallopian Tube Cancer Stage III
- Interventions
- Microdevice
- Combination Product
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer (Locally Advanced or Metastatic)
- Interventions
- Pemefolacianine Cohort 1 in Part A, Pemefolacianin Cohort 2 in Part B
- Drug
- Lead sponsor
- Sunil Singhal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Anastrozole, Doxorubicin Hydrochloride, Exemestane, Laboratory Biomarker Analysis, Letrozole, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 6
- States / cities
- Corona, California • Duarte, California • Lancaster, California + 3 more
- Conditions
- IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
- Interventions
- Atrasentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 14
- States / cities
- Glendale, California • Los Angeles, California • San Dimas, California + 11 more
- Conditions
- Smoking, Nicotine Dependence
- Interventions
- No intervention: observation only
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 422 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Madison, Wisconsin • Milwaukee, Wisconsin
- Conditions
- Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy
- Interventions
- Stelara (ustekinumab)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin, Avelumab
- Drug
- Lead sponsor
- BicycleTx Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Miami, Florida • Miami Beach, Florida + 10 more
- Conditions
- Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
- Interventions
- tusamitamab ravtansine, Gemcitabine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Boston, Massachusetts • Madison, Wisconsin
- Conditions
- Healthy Volunteer
- Interventions
- REGN6490, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- Blinatumomab, Pembrolizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- La Jolla, California • Charleston, South Carolina • Greenville, South Carolina
- Conditions
- COVID-19, Undefined
- Interventions
- AT-100
- Biological
- Lead sponsor
- Airway Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC), Tumors Metastatic to Brain, Metastatic Breast Cancer (mBC)
- Interventions
- Pegylated Irinotecan
- Drug
- Lead sponsor
- Joel Neal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
- Interventions
- CT-0508, Pembrolizumab
- Biological
- Lead sponsor
- Carisma Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
- Interventions
- IM JZP-458, IV JZP-458
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 8 more
- Conditions
- Endometrial Cancer
- Interventions
- Hypofractionated Radiation, Clinical Follow-Up and Assessments
- Radiation · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Houston, Texas + 1 more
- Conditions
- Transplant Rejection
- Interventions
- BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
- Conditions
- Neoplasms
- Interventions
- Vemurafenib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Ulcerative Colitis
- Interventions
- Etrozulimab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more
- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
- Interventions
- ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more